Published on 22/12/2025
Comparing Early and Late Phase Trials in Immuno-Oncology
Introduction to Immuno-Oncology Clinical Development
Immuno-oncology (I-O) has transformed cancer treatment, introducing therapies that harness the immune system to recognize and destroy tumor cells. The clinical development of I-O agents follows the traditional phase-based pathway—Phase I (early), Phase II, Phase III (late), and Phase IV post-marketing—but with unique considerations related to immune biology. The transition from early to late phases involves shifts in trial objectives, endpoints, patient populations, and regulatory expectations.
Understanding the distinctions between early and late phase trials is critical for optimizing development timelines, ensuring patient safety, and generating robust evidence for regulatory approval. Agencies such as the EMA and FDA require tailored strategies for I-O programs, given their potential for atypical response patterns and delayed toxicities.
Objectives of Early vs Late Phase Trials
In early-phase I-O trials (Phases I and I/II), the primary objectives focus on safety, tolerability, and identifying an optimal biological dose (OBD) rather than the traditional maximum tolerated dose (MTD). Immune-based therapies, such as checkpoint inhibitors or CAR-T cells, often exhibit a plateau in dose–response relationships, making OBD determination critical. Biomarker exploration—such as PD-L1 expression or tumor
In late-phase trials (Phases III and IV), the emphasis shifts to demonstrating clinical efficacy in large, diverse patient populations. Here, endpoints include overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), alongside continued safety monitoring. Combination strategies, sequencing of treatments, and comparisons to standard-of-care regimens dominate late-phase trial objectives.
Trial Design Differences
Early-phase I-O trials often use adaptive designs, basket trials, or umbrella trials to rapidly explore safety and efficacy signals across multiple tumor types or biomarker-defined subgroups. These designs allow efficient identification of responsive populations and facilitate faster progression to later phases. Cohort expansion at the recommended phase II dose (RP2D) is common to refine the understanding of efficacy and safety in targeted subpopulations.
Late-phase trials are typically randomized controlled trials (RCTs) with larger sample sizes and fixed protocols. They require robust statistical powering to detect meaningful clinical differences between arms. Double-blind, placebo-controlled designs are preferred when feasible, though open-label trials are common when blinding is impractical.
Endpoints and Response Criteria
In early-phase I-O trials, exploratory endpoints like immune-related response rate (irRR), immune-related progression-free survival (irPFS), and biomarker changes are prioritized. The iRECIST criteria, which account for atypical immune responses such as pseudoprogression, are increasingly used for tumor assessments.
In late-phase settings, endpoints are more definitive and regulatory-focused—OS, PFS, and duration of response (DoR). Hierarchical testing strategies may be used to control type I error rates when multiple primary endpoints are evaluated. Central imaging review and independent data monitoring are crucial to ensure unbiased endpoint assessment.
Safety Monitoring and Immune-Related Adverse Events (irAEs)
Safety monitoring differs substantially between early and late phases. Early-phase trials implement intensive safety assessments, including frequent lab tests, imaging, and clinical evaluations to identify dose-limiting toxicities (DLTs) and characterize immune-related adverse events (irAEs). Late-phase trials, while still vigilant, may use more streamlined safety monitoring once the toxicity profile is well characterized.
Management of irAEs requires specialized protocols, including corticosteroid use for immune-mediated colitis, hepatitis, or pneumonitis. Education of investigators and site staff on early recognition and management of irAEs is critical across all phases.
Role of Translational Research
Translational research bridges laboratory discoveries with clinical application, playing a central role in I-O development. In early phases, this may involve collecting serial tumor biopsies and blood samples to analyze immune cell infiltration, cytokine profiles, and other biomarkers. These data inform patient selection strategies, combination therapy approaches, and mechanistic understanding.
In late phases, translational research focuses on validating predictive biomarkers, understanding mechanisms of resistance, and identifying potential biomarkers for subsequent therapy lines. Integration of translational endpoints into pivotal trials enhances the scientific value of the data package submitted for regulatory review.
Regulatory Considerations for Immuno-Oncology
Regulators have adapted guidelines to address the unique characteristics of I-O therapies. For early-phase trials, the emphasis is on detailed safety characterization, robust biomarker development plans, and early engagement with agencies to align on trial designs. For late-phase trials, regulators expect mature survival data, validated companion diagnostics (if applicable), and comprehensive safety follow-up extending beyond trial completion.
Collaborative initiatives like the FDA’s Oncology Center of Excellence and EMA’s PRIME scheme offer pathways for expedited development of promising I-O therapies, particularly when supported by strong early-phase data.
Case Study: PD-1 Inhibitor Development
A PD-1 inhibitor began development in a Phase I dose-escalation study involving multiple tumor types. Early cohorts established the OBD at 200 mg every 3 weeks based on safety and PD-L1 biomarker data. Expansion cohorts in Phase II confirmed high response rates in melanoma and NSCLC. The program then transitioned to Phase III trials comparing the drug against standard chemotherapy, demonstrating OS benefits across multiple cancers, leading to global approvals.
This case illustrates how strategic early-phase design, coupled with robust translational research, can accelerate progression to successful late-phase trials and regulatory approval.
Operational and Logistical Considerations
Operational needs evolve from early to late phases. Early trials often require fewer sites with specialized expertise in managing I-O toxicities, while late-phase trials expand globally to recruit larger patient populations. Data management complexity increases, necessitating advanced EDC systems, real-time safety reporting, and global coordination.
Site training, patient recruitment strategies, and drug supply logistics must adapt to the changing scope and requirements of each phase. Leveraging resources such as PharmaValidation can support consistent quality and compliance across development stages.
Conclusion
Early and late phase trials in immuno-oncology differ significantly in objectives, design, endpoints, and operational requirements, yet they are interdependent components of the drug development continuum. Success in late-phase trials is often predicated on the quality of early-phase data, including biomarker insights and safety characterization. By strategically aligning scientific, operational, and regulatory strategies across phases, sponsors can optimize the development of transformative immuno-oncology therapies.
Looking ahead, the increasing use of platform trials, real-world evidence integration, and AI-driven analytics will further blur the boundaries between early and late phases, enabling more efficient and patient-centered I-O development pathways.